Client News

Formycon AG Presents Clinical Data on Ustekinumab Biosimilar FYB202 at the ECCO Congress in Berlin

MIG Capital Navigates a Demanding Market Environment in 2024 and Looks Ahead to 2025 with Cautious Optimism

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

VisionHealth Announces Management Transition as Company Prepares for U.S. Launch of Kata® App

Formycon AG Informs about Recent Developments in Various Biosimilar Projects and Invites to Conference Call

Volta Medical Artificial Intelligence-Guided Cardiac Ablation Procedure Improves Treatment of Atrial Fibrillation

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Lindis Biotech and Pharmanovia Announce European Marketing Authorisation Approval for Catumaxomab, a First-in-Class Treatment for Malignant Ascites